2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-181257
    GLP-1 receptor agonist 18 3112736-36-1 98%
    GLP-1 receptor agonist 18 is an orally active GLP-1 receptor agonist with an EC50 of 0.22 nM. GLP-1 receptor agonist 18 can reduces blood sugar levels and body weight. GLP-1 receptor agonist 18 can be used for the research of diabetes.
    GLP-1 receptor agonist 18
  • HY-181519
    ALR2/α-GLY-IN-1 98%
    ALR2/α-GLY-IN-1 is a potent dual-target inhibitor that targets aldose reductase ALR2 and α-glucosidase (IC50 values are 0.72 μM and 0.82 μM, respectively; Ki values are 1.67 μM and 1.37 μM, respectively). ALR2/α-GLY-IN-1 also acts as a DNA binder, which stably interacts with calf thymus double-stranded DNA through non-covalent interactions such as groove-binding mode and water-bridged hydrogen bonds. ALR2/α-GLY-IN-1 can be used in studies related to diabetes and its complications.
    ALR2/α-GLY-IN-1
  • HY-181520
    ABCA1 inducer 3 2681270-30-2
    ABCA1 inducer 3 (Compound 85) is an orally active ABCA1 inducer and lipid-modulating agent. ABCA1 inducer 3 increases ABCA1 expression. ABCA1 inducer 3 upregulates hepatic Abcg5 and Abcg8 mRNA expression. ABCA1 inducer 3 promotes cholesterol efflux. ABCA1 inducer 3 improves hyperlipidemia.
    ABCA1 inducer 3
  • HY-181563
    MGAT2-IN-6
    MGAT2-IN-6 (Compound 23AX) is an orally active MGAT2 inhibitor. MGAT2-IN-6 reduces triglyceride levels and liver fibrosis. MGAT2-IN-6 can be used in the research of metabolic dysfunction-associated fatty liver disease.
    MGAT2-IN-6
  • HY-181564
    MGAT2-IN-7 3115123-06-0 98%
    MGAT2-IN-7 is an orally active monoacylglycerol acyltransferase 2 (MGAT2) inhibitor. MGAT2-IN-7 is used for research on obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).
    MGAT2-IN-7
  • HY-181619
    TAO Kinase-IN-3 3114565-22-6 98%
    TAO Kinase-IN-3 is a potent pan-TAOK (Thousand-And-One Kinase) inhibitor that specifically binds to and inhibits the kinase activities of TAOK1, TAOK2 and TAOK3 with Kd values of <0.17 nM, 0.34 nM, and 0.17 nM, respectively. TAO Kinase-IN-3 can be used to study Alzheimer's disease, primary tauopathies and related syndromes. In addition, TAO Kinase-IN-3 is also widely used in research on the mechanisms of cancer cachexia and the muscle atrophy it induces.
    TAO Kinase-IN-3
  • HY-181638
    4-Cl-Benzodioxolyl chalcone 934022-22-7 98%
    4-Cl-Benzodioxolyl chalcone is a type of chalcone. It reduces the viability of endometriotic cells while maintaining or increasing the viability of normal endometrial cells. 4-Cl-Benzodioxolyl chalcone can be used in the research of endometriosis.
    4-Cl-Benzodioxolyl chalcone
  • HY-182294
    HYJ-2
    HYJ-2 is a URAT1 inhibitor and urate-lowering agent. HYJ-2 inhibits URAT1-mediated urate transport and interacts with key residues within the URAT1 binding pocket. HYJ-2 reduces serum urate levels in hyperuricemic mice without inducing liver or kidney injury. HYJ-2 shows low cytotoxicity to hepatocytes and renal cells. HYJ-2 does not significantly induce hepatocyte apoptosis or mitochondrial dysfunction. HYJ-2 can be used in studies related to hyperuricemia and gout.
    HYJ-2
  • HY-182773
    MC4R Antagonist-1 98%
    MC4R Antagonist-1 (compound 1) is an MC4R-selective antagonist (IC50<10 nM). MC4R Antagonist-1 can be used for the research of cachexia, anorexia, anorexia nervosa, involuntary weight loss, failure to thrive, sarcopenia, muscle wasting, muscle weakness, frailty, osteoporosis.
    MC4R Antagonist-1
  • HY-18282R
    AZ876 (Standard) 898800-26-5 98%
    AZ876 (Standard) is the analytical standard of AZ876. This product is intended for research and analytical applications. AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis.
    AZ876 (Standard)
  • HY-182960
    KRP-203 monophosphate 749262-82-6
    KRP-203 monophosphate is a monophosphate of KRP-203 (HY-13660). KRP-203 is an orally active sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs.
    KRP-203 monophosphate
  • HY-182989
    Tyrosinase-IN-50 3081328-14-2 98%
    Tyrosinase-IN-50 (Compound 14) is a Tyrosinase inhibitor (IC50 is 0.06 μM or 0.16 μM). Tyrosinase-IN-50 inhibits melanogenesis in multiple cell types. Tyrosinase-IN-50 can be used for the research of hyperpigmentation-related diseases and inflammatory diseases.
    Tyrosinase-IN-50
  • HY-183342
    DHEA Benzophenone-biotin 1216903-70-6 98%
    DHEA Benzophenone-biotin is a photoactive DHEA (HY-14650) analog containing Biotin (HY-B0511) and Benzophenone (HY-Y0546) groups. DHEA Benzophenone-biotin inhibits plasma membrane binding of DHEA, activates endothelial NO synthase. DHEA Benzophenone-biotin cross-links to plasma membrane DHEA binding sites upon UV irradiation to identify associated proteins.
    DHEA Benzophenone-biotin
  • HY-18346R
    Mozavaptan (Standard) 137975-06-5 98%
    Mozavaptan (Standard) is the analytical standard of Mozavaptan. This product is intended for research and analytical applications. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.
    Mozavaptan (Standard)
  • HY-183855
    WF-2421 128429-19-6
    WF-2421 is an aldose reductase inhibitor with an IC50 of 0.03 μM against rabbit-derived aldose reductase. WF-2421 acts as a non-competitive inhibitor of aldose reductase using dl-glyceraldehyde as the substrate. WF-2421 can be used in the research of diabetic complications (cataract, neuropathy, retinopathy, nephropathy).
    WF-2421
  • HY-183871
    WMS-1410 1253197-38-4
    WMS-1410 is a selective GluN2B-containing NMDA receptor inhibitor with an IC50 of 18.4 nM. WMS-1410 regulates intracellular calcium levels and protects cells from Apoptosis. WMS-1410 inhibits glutamate-induced excitotoxicity. WMS-1410 reverses NMDA/glycine-induced reduction in glucose-stimulated insulin secretion without altering physiological insulin secretion or baseline redox status, but fails to counteract insulin content loss induced by glucolipotoxicity. WMS-1410 exhibits analgesic activity against advanced neuropathic pain. WMS-1410 can be used in studies related to stroke, brain injury, Alzheimer's disease, Parkinson's disease, type 2 diabetes, and neuropathic pain.
    WMS-1410
  • HY-183878
    Zincov 71431-46-4 98%
    Zincov is an orally active hydroxamic acid derivative and bacterial metalloproteinase inhibitor. Zincov blocks chloride ion binding by binding to the active site of thermolysin, thereby inhibiting the hydrolysis and blood coagulation reactions catalyzed by this enzyme. Meanwhile, Zincov attenuates cytotoxicity, prevents protein degradation and ZO-1 rearrangement without affecting the functions of other common proteases. Zincov exhibits blood glucose-regulating and antioxidant activities; it reduces blood glucose levels and increases liver dry weight in diabetic rats, but elevates blood glucose levels in normal rats. Zincov is widely used in studies related to cholera and diabetes.
    Zincov
  • HY-183919
    ACC2-IN-1 2237229-78-4
    ACC2-IN-1 is an orally active, selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), with an IC50 of 1.9 nM against human targets. ACC2-IN-1 acts as a reducing agent to decrease malonyl-CoA levels in skeletal muscle and exhibits a favorable CYP450 inhibition profile. ACC2-IN-1 can be used in the research of type 2 diabetes.
    ACC2-IN-1
  • HY-183923
    SX 3202 147254-65-7
    SX 3202 is an aldose reductase inhibitor. SX 3202 can be used for the research of diabetic complications.
    SX 3202
  • HY-183955
    GNF7156 2041071-54-7
    GNF7156 is a DYRK1A/GSK3B inhibitor, IC50 values of 100 nM for DYRK1A and 40 nM for GSK3B. GNF7156 inhibits DYRK1A and GSK3B kinase activity and induces NFAT nuclear retention. GNF7156 stimulates beta-cell cycle entry and division and maintains insulin secretory capacity. GNF7156 can be used for the research of type 1 diabetes, and type 2 diabetes.
    GNF7156
Cat. No. Product Name / Synonyms Application Reactivity